Invest in intelligence that delivers

US Gastroenterologists Express Anticipation for Approval of AbbVie’s Skyrizi in Ulcerative Colitis, Projecting Rapid Adoption Post-Launch 

Despite enthusiasm for Skyrizi, key updates for various developmental assets in ulcerative colitis were released at Digestive Disease Week, holding the potential to impact sentiments.   Exton, PA., June 12, 2024 – Despite being the second IL-23 inhibitor to enter the market, AbbVie’s Skyrizi (risankizumab) is expected to have a substantial impact on ulcerative colitis (UC) […]

‘Efficacy will lead’ as first-line JAK inhibitor use picks up in moderate to severe UC

Despite a class-wide black box warning for prescribing in the early setting, 31% of providers reported positioning Janus kinase inhibitors as first-line treatment among patients with severe ulcerative colitis, according to survey results. “Where it is positioned in the label today is after an anti-TNF, meaning that patients had to have been on some form of TNF […]

First ever MASH drug primed for big impact in USA

Research suggests there will likely be strong uptake for the first USA-approved therapy for metabolic dysfunction-associated steatohepatitis (MASH). Madrigal Pharmaceuticals (Nasdaq: MDGL) recently scored a US Food and Drug Administration (FDA) nod for Rezdiffra (resmetirom) as a treatment for MASH, alongside diet and exercise. As the first prescription medicine for a large treatment opportunity, Rezdiffra has the […]

Docs sing praises of Madrigal’s Rezdiffra, predict rapid uptake

Madrigal Pharmaceuticals already has physicians singing from its hymn sheet. Shortly after the biotech won approval in metabolic dysfunction-associated steatohepatitis (MASH), most gastroenterologists said they were familiar with its drug and planning to trial the brand within six months of its launch. Spherix Global Insights captured the views in a survey that asked 81 gastroenterologists for their […]

US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Excitement grows as the FDA’s first approval for MASH treatment nears commercialization, according to Spherix Global Insights.  Exton, PA., April 5, 2024 – As the first treatment to gain FDA approval for metabolic dysfunction-associated steatohepatitis (MASH), Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) is poised to make a sizable impact on a condition with substantial unmet need. As […]

Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for the Treatment of Ulcerative Colitis, but Future Projections Reveal a Highly Evolving Market

Takeda’s line extension has outpaced other concurrent launches in adoption and familiarity three months post launch, according to Spherix Global Insights. Exton, PA., March 22, 2024 – The end of 2023 introduced several new treatment options for patients suffering from ulcerative colitis (UC). Among them is Eli Lilly’s Omvoh (mirikizumab), the first FDA approved IL-23 […]

US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape Afoot, with Launches of Eli Lilly’s Omvoh, Pfizer’s Velsipity, Takeda’s Subcutaneous Entyvio, and Celltrion’s Zymfentra

Prior to launch, prescribers estimate that TNF inhibitors are likely to bear the greatest brunt of increased adoption of the newest market entrants, according to Spherix Global Insights [Exton PA, November 13, 2023] — In the past two months, the landscape of available treatments for ulcerative colitis (UC) has undergone a significant expansion, marked by […]

Amgen’s Amjevita Remains the Frontrunner in the US Adalimumab Biosimilars Market, Despite Increased Competition, According to Spherix Global Insights.

Boehringer Ingelheim’s Cyltezo has a slight competitive edge over other concurrent biosimilar launches on certain key performance metrics, though prescriber future projections show little differentiation in use among the recent entrants. Exton, PA, September 14, 2023 — This summer ushered in the highly anticipated introduction of a multitude of additional adalimumab biosimilars to the dynamic […]

Sign up for alerts, market insights and exclusive content in your inbox.

Spherix is excited to announce our expansion into an additional, rapidly evolving specialty market:


Throughout 2024, we will be publishing over
10 groundbreaking studies covering a wide range of indications within classical hematology.